News | December 21, 2009

Guidelines Updated for Perioperative Beta-Blockade

December 21, 2009 – Revised guidelines on the use of beta-blockers for noncardiac surgery say therapy should neither be initiated on the day of surgery, nor stopped abruptly peri- or postoperatively.

In response to publication of the POISE trial results in 2008, this focused update of the 2007 American College of Cardiology/American Heart Association guidelines addresses the prophylactic use of beta-blockers to minimize cardiac risk during surgery. In addition to revised recommendations, the update provides a comprehensive summary of the literature on perioperative beta-blocker therapy.

This focused update explains the role of prophylactic perioperative beta-blocker therapy in different clinical scenarios. Patients already taking a beta-blocker should continue taking it. In patients who would benefit from a beta-blocker, it should be started well in advance of the surgical procedure and titrated to heart rate and blood pressure. Beta-blocker therapy should be neither initiated on the day of surgery nor stopped abruptly peri- or postoperatively.

Key points in the new guidelines include:

• Beta-blockers should be continued in patients undergoing surgery who are currently taking beta-blockers for treatment of indicated conditions (class I).

• Beta-blockers titrated to heart rate and blood pressure can be beneficial in patients undergoing vascular surgery who have coronary artery disease (CAD) or cardiac ischemia identified during preoperative assessment (class IIa).

• Beta-blockers titrated to heart rate and blood pressure are reasonable in patients undergoing vascular surgery who have more than one clinical risk factor for CAD identified during preoperative assessment (class IIa).

• Beta-blockers titrated to heart rate and blood pressure are reasonable in patients undergoing intermediate-risk surgery who have CAD or more than one clinical risk factor identified during preoperative assessment (class IIa).

• In patients undergoing intermediate-risk or vascular surgery with a single clinical risk factor identified during preoperative assessment, the usefulness of beta-blockers is uncertain (class IIb).

• In patients undergoing vascular surgery who are not currently taking beta-blockers and have no clinical risk factors, the usefulness of beta-blockers is uncertain (class IIb).

• In patients undergoing noncardiac surgery who are not currently taking beta-blockers, routine administration of high-dose, untitrated perioperative beta-blockers is not recommended (class III).

• Perioperative withdrawal of beta-blockers should be avoided unless absolutely necessary.

• In general, beta-blockers should be started well in advance of a planned procedure and carefully titrated perioperatively to achieve adequate heart rate control.

The new guidelines are endorsed by the American College of Cardiology, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, and the Society for Vascular Surgery

The update appeared in the Nov. 24, 2009 issue of Circulation (Fleischmann K. E. et al. “ACCF/AHA focused update on perioperative beta blockade.” 120:2123).

For more information: circ.ahajournals.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
Overlay Init